Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phoenix Laser Systems

This article was originally published in The Gray Sheet

Executive Summary

Files statement with the Securities and Exchange Commission related to its plan to reorganize the company. Under the plan, Phoenix' two core businesses will be separated into two new companies: Advanced Medical Lasers, Inc. and Optronics Technologies, Inc., both of which eventually will be spun off with Phoenix retaining partial ownership. The firm's ophthalmic laser workstation and the related technology will become part of AML. Phoenix is in negotiations to acquire Refractive Laser Research Partners, a limited partnership based in San Antonio, Texas that is developing a hand-held laser probe; RLRP would also be incorporated into AML. A $2.5 mil. private placement for AML is sought, after which a merger with a publicly traded company would serve as a means to spin off the business. Phoenix' Optronics Technologies business would be composed partly of its current subsidiary, Optronics, minus Optronics' 88% owned intraocular lens manufacturing business, DGR, which Phoenix plans to sell. The remaining part of Optronics is essentially the marketing arm, and Optronics would seek to continue selling the IOLs under an agreement with DGR. Phoenix also is in negotiations to acquire Mastel Precision Instruments, a South Dakota firm that manufactures and markets diamond knives and related equipment for refractive surgery. If an acquisition deal is reached, MPI would be folded into Optronics Technologies. OTI will then seek to raise $2.5 mil. to $5 mil. through a private placement, after which a merger with another publicly traded company would serve as a means to spin off the business.

You may also be interested in...



ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

UsernamePublicRestriction

Register

MT000477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel